15 Advanced Solid Tumors Clinical Trials in Indianapolis, IN (2026)

Q: How do I join a clinical trial in Indianapolis?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Indianapolis research site will contact you.

Recruiting Advanced Solid Tumors Studies in Indianapolis

NCT06081517Recruiting

Evaluating Disparities in Precision Oncology

This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehen...

Indianapolis, IN10,600 participantsIndiana University

View Study Details

NCT06581432Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of th...

Indianapolis, INPHASE2430 participantsBoehringer Ingelheim

View Study Details

NCT06465069Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The ...

Indianapolis, INPHASE1420 participantsEli Lilly and Company

View Study Details

NCT06625775Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced...

Indianapolis, INPHASE1392 participantsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

View Study Details

NCT05669430Recruiting

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care....

Indianapolis, INPHASE1365 participantsGV20 Therapeutics

View Study Details

NCT06752681Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate in participants with advanced o...

Indianapolis, INPHASE1254 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT05970497Recruiting

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid ...

Indianapolis, INPHASE1240 participantsKrystal Biotech, Inc.

View Study Details

NCT05100342Recruiting

Prospective Validation of a Points Score System Predicting 30-day Survival

This is a one-stage single-arm phase II clinical trial designed to prospectively test the survival prediction tool as developed by Lee et al on patients referred to radiation oncology for palliative t...

Indianapolis, IN214 participantsIndiana University

View Study Details

NCT05902988Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers....

Indianapolis, INPHASE1200 participantsVolastra Therapeutics, Inc.

View Study Details

NCT06956690Recruiting

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ENV-501 in Patients With HER3-Expressing Solid Tumors

This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of ENV-501 in patients with advanced-stage, relapsed...

Indianapolis, INPHASE1180 participantsEndeavor Biomedicines, Inc.

View Study Details

NCT04851119Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to tr...

Indianapolis, INPHASE1147 participantsChildren's Oncology Group

View Study Details

NCT06414460Recruiting

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability o...

Indianapolis, INPHASE1114 participantsInSilico Medicine Hong Kong Limited

View Study Details

NCT06620302Recruiting

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors a...

Indianapolis, INPHASE181 participantsChildren's Oncology Group

View Study Details

NCT06444815Recruiting

A Study of VET3-TGI in Patients With Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET...

Indianapolis, INPHASE160 participantsKaliVir Immunotherapeutics

View Study Details

NCT06187402Recruiting

A Study of LM-24C5 For Advanced Solid Tumors

To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors....

Indianapolis, INPHASE149 participantsLaNova Medicines Limited

View Study Details

About Advanced Solid Tumors Clinical Trials in Indianapolis

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 15 advanced solid tumors clinical trials recruiting participants in Indianapolis, IN. These studies are seeking a combined 13,746 participants. Research is being sponsored by Indiana University, Boehringer Ingelheim, Eli Lilly and Company and 10 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Indianapolis — FAQ

Are there advanced solid tumors clinical trials in Indianapolis?

Yes, there are 15 advanced solid tumors clinical trials currently recruiting in Indianapolis, IN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Indianapolis?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Indianapolis research site will contact you about next steps.

Are clinical trials in Indianapolis free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Indianapolis studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 15 active trials in Indianapolis are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated July 17, 2026 from ClinicalTrials.gov